BioHarvest Inks 20-Ton Supply Deal for Rare Fragrance, Eyes $20-30M Revenue
BHST sits 16% above its 52-week low of $1.82 on elevated volume (2.4× avg).
Summary
BioHarvest secured an exclusive manufacturing and supply agreement for a rare, endangered fragrance plant cell culture with an undisclosed UAE customer. The deal reserves capacity for 20 metric tons of product, with production starting in H1 2027, and could generate $20–$30 million in revenue upon delivery. This marks the company's entry into the luxury fragrance market, leveraging its Botanical Synthesis platform beyond nutraceuticals and food ingredients. The agreement follows the May 2026 Stage 1 development milestone for the same rare plant and expands on an existing partnership. With premium grades of this scent commanding tens of thousands of dollars per kilogram, the deal validates the platform's scalability and opens a high-margin, regulation-light revenue stream. The fragrance industry's supply challenges and demand for sustainable ingredients position BioHarvest for further CDMO contracts in this space.
At the time of this announcement, BHST was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.6M. The 52-week trading range was $1.82 to $12.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.